Arbutus Biopharma Corporation (ABUS)

Arbutus Biopharma (ABUS) Stock Price & Analysis


ABUS Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.85 - $3.22
Previous Close$2.99
Average Volume (3M)965.69K
Market Cap
Enterprise Value$341.36M
Total Cash (Recent Filing)$146.91M
Total Debt (Recent Filing)$2.19M
Price to Earnings (P/E)-6.5
May 04, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.46
Shares Outstanding157,500,000
10 Day Avg. Volume761,064
30 Day Avg. Volume965,691
Standard Deviation0.29
Financial Highlights & Ratios
Price to Book (P/B)2.97
Price to Sales (P/S)13.17
Price to Cash Flow (P/CF)7665.10
P/FCF Ratio-23.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue8.75
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-5.52
Price Target Upside98.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Arbutus Biopharma Corporation’s price range in the past 12 months?
Arbutus Biopharma Corporation lowest stock price was $1.85 and its highest was $3.22 in the past 12 months.
    What is Arbutus Biopharma Corporation’s market cap?
    Currently, no data Available
    When is Arbutus Biopharma Corporation’s upcoming earnings report date?
    Arbutus Biopharma Corporation’s upcoming earnings report date is May 04, 2023 which is in 44 days.
      How were Arbutus Biopharma Corporation’s earnings last quarter?
      Arbutus Biopharma Corporation released its earnings results on Mar 02, 2023. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.134 by $0.004.
        Is Arbutus Biopharma Corporation overvalued?
        According to Wall Street analysts Arbutus Biopharma Corporation’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Arbutus Biopharma Corporation pay dividends?
          Arbutus Biopharma Corporation does not currently pay dividends.
          What is Arbutus Biopharma Corporation’s EPS estimate?
          Arbutus Biopharma Corporation’s EPS estimate is -$0.14.
            How many shares outstanding does Arbutus Biopharma Corporation have?
            Arbutus Biopharma Corporation has 162,570,980 shares outstanding.
              What happened to Arbutus Biopharma Corporation’s price movement after its last earnings report?
              Arbutus Biopharma Corporation reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.134. Following the earnings report the stock price went same 0%.
                Which hedge fund is a major shareholder of Arbutus Biopharma Corporation?
                Among the largest hedge funds holding Arbutus Biopharma Corporation’s share is PRIMECAP Management Co. It holds Arbutus Biopharma Corporation’s shares valued at 819K.


                  Arbutus Biopharma Stock Smart Score

                  The Arbutus Biopharma stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Arbutus Biopharma Corporation

                  Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company is headquartered in Burnaby, Canada.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Scholar Rock Holding
                  Lexicon Pharmaceuticals
                  Poseida Therapeutics
                  C4 Therapeutics

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis